On Monday 27 November 2023, we were delighted to welcome Madiha Derouazi, CEO of Speransa Therapeutics, founder and former CEO of Amal Therapeutics, Alumni Award 2023 and EPFL alumna.
"From Scientist to Entrepreneur: Bridging the Gap to Bring Vaccines to the Clinic"
At the conference, Madiha Derouazi shared her experiences and lessons about the transition from scientist to entrepreneur, and presented her research.
After obtaining her doctorate from EPFL in 2005, Madiha Derouazi embarked on an adventure that few believed in: creating a vaccine to treat cancer.
About Madiha Derouazi
Madiha Derouazi has been working on vector engineering and vaccine design for over 15 years. In 2012, she founded AMAL Therapeutics, a biotech company developing therapeutic cancer vaccines. The company was acquired by Boehringer Ingelheim in July 2019 for CHF425 million. She is now the CEO of Speransa Therapeutics, a clinical-stage Biotech with a Focus on COVID-19 Vaccine Development.
Madiha Derouazi holds a Master's degree from Berlin's Technische Universität, followed by a PhD in biotechnology from EPFL in 2005. She was awarded the European Inventor Prize in 2022. At this year's Magistrale, she received an "Alumni Award" from the School for the exceptional quality of her entrepreneurial career.
Image gallery10
Comments0
Please log in to see or add a comment
Suggested Articles
